Saturday, 7 November 2026European Markets

NORSKE SKOG Stock Is 10% Down So Far On Thursday

Loading stream...

(VIANEWS) - Shares of NORSKE SKOG (Oslo Børs Benchmark Index_GI: NSKOG.OL) fell by a staggering 10.14% to kr46.50 at 14:37 EST on Thursday, after two sequential sessions in a row of losses. Oslo Børs Benchmark Index_GI is rising 0.2% to kr1,207.20, following the last session's upward trend. This seems, as yet, a somewhat up trend exchanging session today.

NORSKE SKOG's last close was kr51.75, 34.37% under its 52-week high of kr78.85.

About NORSKE SKOG

Norske Skog ASA produces and sells newsprint and magazine papers. It operates in two segments, Publication Paper Europe, and Publication Paper Australasia. The company offers standard newsprint and other papers; and magazine paper comprising super calendared and lightweight coated magazine paper. Its products are primarily used in newspapers and magazines, catalogues, advertising materials, inserts/flyers, supplements, free-sheets, directories, direct mail, and book papers. The company operates in Norway, rest of Europe, North America, Australasia, Asia, and Africa. Norske Skog ASA was founded in 1962 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, NORSKE SKOG has a trailing twelve months EPS of kr26.19.

PE Ratio

NORSKE SKOG has a trailing twelve months price to earnings ratio of 1.78. Meaning, the purchaser of the share is investing kr1.78 for every norwegian krone of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 56.89%.

More news about NORSKE SKOG (NSKOG.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com